nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—Opioid Antagonists—Naltrexone—alcohol dependence	0.328	1	CiPCiCtD
Methylnaltrexone—Naltrexone—alcohol dependence	0.235	1	CrCtD
Methylnaltrexone—OPRK1—alcohol dependence	0.101	0.65	CbGaD
Methylnaltrexone—OPRK1—Naltrexone—alcohol dependence	0.0549	0.499	CbGbCtD
Methylnaltrexone—OPRM1—alcohol dependence	0.0545	0.35	CbGaD
Methylnaltrexone—OPRM1—Naltrexone—alcohol dependence	0.0484	0.44	CbGbCtD
Methylnaltrexone—Buprenorphine—Naltrexone—alcohol dependence	0.0333	0.216	CrCrCtD
Methylnaltrexone—Nalbuphine—Naltrexone—alcohol dependence	0.0221	0.144	CrCrCtD
Methylnaltrexone—Naloxone—Naltrexone—alcohol dependence	0.0221	0.144	CrCrCtD
Methylnaltrexone—Oxymorphone—Naltrexone—alcohol dependence	0.0221	0.144	CrCrCtD
Methylnaltrexone—Oxycodone—Naltrexone—alcohol dependence	0.0205	0.133	CrCrCtD
Methylnaltrexone—Hydrocodone—Naltrexone—alcohol dependence	0.0169	0.11	CrCrCtD
Methylnaltrexone—Hydromorphone—Naltrexone—alcohol dependence	0.0169	0.11	CrCrCtD
Methylnaltrexone—CYP2D6—Citalopram—alcohol dependence	0.00665	0.0604	CbGbCtD
Methylnaltrexone—OPRM1—nerve—alcohol dependence	0.000456	0.156	CbGeAlD
Methylnaltrexone—OPRK1—forebrain—alcohol dependence	0.000266	0.0911	CbGeAlD
Methylnaltrexone—Injection site reaction—Naltrexone—alcohol dependence	0.000243	0.0749	CcSEcCtD
Methylnaltrexone—OPRM1—brainstem—alcohol dependence	0.000196	0.0672	CbGeAlD
Methylnaltrexone—OPRM1—forebrain—alcohol dependence	0.000189	0.0648	CbGeAlD
Methylnaltrexone—Pain—Disulfiram—alcohol dependence	0.00016	0.0493	CcSEcCtD
Methylnaltrexone—OPRK1—nervous system—alcohol dependence	0.000144	0.0495	CbGeAlD
Methylnaltrexone—OPRK1—central nervous system—alcohol dependence	0.000139	0.0476	CbGeAlD
Methylnaltrexone—OPRK1—cerebellum—alcohol dependence	0.000136	0.0465	CbGeAlD
Methylnaltrexone—OPRM1—blood—alcohol dependence	0.000126	0.0433	CbGeAlD
Methylnaltrexone—OPRM1—Opioid Signalling—PDYN—alcohol dependence	0.000125	0.0131	CbGpPWpGaD
Methylnaltrexone—Nalbuphine—OPRK1—alcohol dependence	0.000125	0.0771	CrCbGaD
Methylnaltrexone—OPRM1—midbrain—alcohol dependence	0.000125	0.0428	CbGeAlD
Methylnaltrexone—Dizziness—Disulfiram—alcohol dependence	0.000124	0.0382	CcSEcCtD
Methylnaltrexone—CYP2D6—Fatty Acid Omega Oxidation—CYP2E1—alcohol dependence	0.000123	0.0128	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Phase 1 - Functionalization of compounds—ADH6—alcohol dependence	0.000117	0.0122	CbGpPWpGaD
Methylnaltrexone—Flatulence—Acamprosate—alcohol dependence	0.000111	0.0343	CcSEcCtD
Methylnaltrexone—OPRK1—brain—alcohol dependence	0.00011	0.0378	CbGeAlD
Methylnaltrexone—OPRM1—endocrine gland—alcohol dependence	0.00011	0.0376	CbGeAlD
Methylnaltrexone—Flatulence—Naltrexone—alcohol dependence	0.000105	0.0325	CcSEcCtD
Methylnaltrexone—OPRM1—testis—alcohol dependence	0.000105	0.0359	CbGeAlD
Methylnaltrexone—CYP2D6—Xenobiotics—CYP2E1—alcohol dependence	0.000103	0.0107	CbGpPWpGaD
Methylnaltrexone—OPRM1—nervous system—alcohol dependence	0.000103	0.0352	CbGeAlD
Methylnaltrexone—Oxymorphone—OPRK1—alcohol dependence	0.000102	0.0629	CrCbGaD
Methylnaltrexone—Naltrexone—OPRK1—alcohol dependence	0.000102	0.0629	CrCbGaD
Methylnaltrexone—CYP2D6—Tamoxifen metabolism—CYP2E1—alcohol dependence	9.89e-05	0.0103	CbGpPWpGaD
Methylnaltrexone—OPRM1—central nervous system—alcohol dependence	9.87e-05	0.0339	CbGeAlD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—OPRK1—alcohol dependence	9.84e-05	0.0103	CbGpPWpGaD
Methylnaltrexone—OPRM1—G-protein activation—POMC—alcohol dependence	9.8e-05	0.0102	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Phase 1 - Functionalization of compounds—ADH1A—alcohol dependence	9.69e-05	0.0101	CbGpPWpGaD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Acamprosate—alcohol dependence	9.54e-05	0.0294	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Naltrexone—alcohol dependence	9.03e-05	0.0279	CcSEcCtD
Methylnaltrexone—Skin disorder—Acamprosate—alcohol dependence	8.95e-05	0.0276	CcSEcCtD
Methylnaltrexone—Hydrocodone—OPRK1—alcohol dependence	8.93e-05	0.055	CrCbGaD
Methylnaltrexone—Hyperhidrosis—Acamprosate—alcohol dependence	8.9e-05	0.0275	CcSEcCtD
Methylnaltrexone—Nalbuphine—OPRD1—alcohol dependence	8.83e-05	0.0544	CrCbGaD
Methylnaltrexone—Oedema—Naltrexone—alcohol dependence	8.71e-05	0.0269	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Naltrexone—alcohol dependence	8.55e-05	0.0264	CcSEcCtD
Methylnaltrexone—Skin disorder—Naltrexone—alcohol dependence	8.46e-05	0.0261	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Naltrexone—alcohol dependence	8.42e-05	0.026	CcSEcCtD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—OPRK1—alcohol dependence	8.3e-05	0.00867	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Phase 1 - Functionalization of compounds—ADH4—alcohol dependence	8.24e-05	0.00861	CbGpPWpGaD
Methylnaltrexone—Oxycodone—OPRK1—alcohol dependence	8.15e-05	0.0502	CrCbGaD
Methylnaltrexone—Gastrointestinal disorder—Acamprosate—alcohol dependence	7.95e-05	0.0245	CcSEcCtD
Methylnaltrexone—Pain—Acamprosate—alcohol dependence	7.88e-05	0.0243	CcSEcCtD
Methylnaltrexone—CYP2D6—brainstem—alcohol dependence	7.85e-05	0.0269	CbGeAlD
Methylnaltrexone—OPRM1—brain—alcohol dependence	7.84e-05	0.0269	CbGeAlD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—OPRD1—alcohol dependence	7.82e-05	0.00818	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—OPRK1—alcohol dependence	7.7e-05	0.00805	CbGpPWpGaD
Methylnaltrexone—CYP2D6—forebrain—alcohol dependence	7.57e-05	0.026	CbGeAlD
Methylnaltrexone—Gastrointestinal pain—Acamprosate—alcohol dependence	7.53e-05	0.0232	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Naltrexone—alcohol dependence	7.52e-05	0.0232	CcSEcCtD
Methylnaltrexone—Buprenorphine—OPRK1—alcohol dependence	7.51e-05	0.0462	CrCbGaD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—PDYN—alcohol dependence	7.5e-05	0.00784	CbGpPWpGaD
Methylnaltrexone—Naloxone—OPRK1—alcohol dependence	7.46e-05	0.0459	CrCbGaD
Methylnaltrexone—Pain—Naltrexone—alcohol dependence	7.45e-05	0.023	CcSEcCtD
Methylnaltrexone—Hydromorphone—OPRK1—alcohol dependence	7.4e-05	0.0456	CrCbGaD
Methylnaltrexone—Abdominal pain—Acamprosate—alcohol dependence	7.28e-05	0.0225	CcSEcCtD
Methylnaltrexone—Oxymorphone—OPRD1—alcohol dependence	7.2e-05	0.0443	CrCbGaD
Methylnaltrexone—Naltrexone—OPRD1—alcohol dependence	7.2e-05	0.0443	CrCbGaD
Methylnaltrexone—Gastrointestinal pain—Naltrexone—alcohol dependence	7.13e-05	0.022	CcSEcCtD
Methylnaltrexone—CYP2D6—Phase 1 - Functionalization of compounds—ADH7—alcohol dependence	7.01e-05	0.00732	CbGpPWpGaD
Methylnaltrexone—Abdominal pain—Naltrexone—alcohol dependence	6.89e-05	0.0213	CcSEcCtD
Methylnaltrexone—Erythema—Citalopram—alcohol dependence	6.76e-05	0.0209	CcSEcCtD
Methylnaltrexone—Nalbuphine—OPRM1—alcohol dependence	6.76e-05	0.0416	CrCbGaD
Methylnaltrexone—Flatulence—Citalopram—alcohol dependence	6.67e-05	0.0206	CcSEcCtD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—OPRD1—alcohol dependence	6.61e-05	0.00691	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—OPRD1—alcohol dependence	6.6e-05	0.0069	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—OPRK1—alcohol dependence	6.6e-05	0.0069	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—PDYN—alcohol dependence	6.34e-05	0.00663	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—PDYN—alcohol dependence	6.33e-05	0.00661	CbGpPWpGaD
Methylnaltrexone—Diarrhoea—Acamprosate—alcohol dependence	6.3e-05	0.0194	CcSEcCtD
Methylnaltrexone—Hydrocodone—OPRD1—alcohol dependence	6.29e-05	0.0387	CrCbGaD
Methylnaltrexone—CYP2D6—Melatonin metabolism and effects—MAOA—alcohol dependence	6.28e-05	0.00657	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—ADH6—alcohol dependence	6.21e-05	0.00649	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Phase 1 - Functionalization of compounds—ADH1B—alcohol dependence	6.14e-05	0.00642	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—OPRD1—alcohol dependence	6.12e-05	0.0064	CbGpPWpGaD
Methylnaltrexone—Dizziness—Acamprosate—alcohol dependence	6.09e-05	0.0188	CcSEcCtD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—OPRM1—alcohol dependence	6.02e-05	0.00629	CbGpPWpGaD
Methylnaltrexone—Diarrhoea—Naltrexone—alcohol dependence	5.96e-05	0.0184	CcSEcCtD
Methylnaltrexone—Vomiting—Acamprosate—alcohol dependence	5.86e-05	0.0181	CcSEcCtD
Methylnaltrexone—Dizziness—Naltrexone—alcohol dependence	5.76e-05	0.0178	CcSEcCtD
Methylnaltrexone—Oxycodone—OPRD1—alcohol dependence	5.74e-05	0.0353	CrCbGaD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Citalopram—alcohol dependence	5.72e-05	0.0177	CcSEcCtD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—OPRD1—alcohol dependence	5.58e-05	0.00583	CbGpPWpGaD
Methylnaltrexone—Vomiting—Naltrexone—alcohol dependence	5.54e-05	0.0171	CcSEcCtD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—NPY—alcohol dependence	5.54e-05	0.00579	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—CHRM2—alcohol dependence	5.53e-05	0.00578	CbGpPWpGaD
Methylnaltrexone—Oedema—Citalopram—alcohol dependence	5.52e-05	0.017	CcSEcCtD
Methylnaltrexone—Oxymorphone—OPRM1—alcohol dependence	5.51e-05	0.0339	CrCbGaD
Methylnaltrexone—Naltrexone—OPRM1—alcohol dependence	5.51e-05	0.0339	CrCbGaD
Methylnaltrexone—Nausea—Acamprosate—alcohol dependence	5.47e-05	0.0169	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Citalopram—alcohol dependence	5.41e-05	0.0167	CcSEcCtD
Methylnaltrexone—Skin disorder—Citalopram—alcohol dependence	5.36e-05	0.0166	CcSEcCtD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—PDYN—alcohol dependence	5.35e-05	0.00559	CbGpPWpGaD
Methylnaltrexone—Hyperhidrosis—Citalopram—alcohol dependence	5.34e-05	0.0165	CcSEcCtD
Methylnaltrexone—CYP2D6—digestive system—alcohol dependence	5.32e-05	0.0182	CbGeAlD
Methylnaltrexone—Buprenorphine—OPRD1—alcohol dependence	5.29e-05	0.0326	CrCbGaD
Methylnaltrexone—Naloxone—OPRD1—alcohol dependence	5.25e-05	0.0323	CrCbGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—OPRD1—alcohol dependence	5.25e-05	0.00548	CbGpPWpGaD
Methylnaltrexone—Hydromorphone—OPRD1—alcohol dependence	5.22e-05	0.0321	CrCbGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—OPRD1—alcohol dependence	5.18e-05	0.00541	CbGpPWpGaD
Methylnaltrexone—Nausea—Naltrexone—alcohol dependence	5.18e-05	0.016	CcSEcCtD
Methylnaltrexone—CYP2D6—Biological oxidations—ADH1A—alcohol dependence	5.15e-05	0.00538	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—CHRM2—alcohol dependence	5.13e-05	0.00536	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Phase 1 - Functionalization of compounds—MAOB—alcohol dependence	5.09e-05	0.00532	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—OPRM1—alcohol dependence	5.08e-05	0.00531	CbGpPWpGaD
Methylnaltrexone—CYP2D6—blood—alcohol dependence	5.06e-05	0.0174	CbGeAlD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—PDYN—alcohol dependence	5.03e-05	0.00526	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—OPRK1—alcohol dependence	5.02e-05	0.00525	CbGpPWpGaD
Methylnaltrexone—Hydrocodone—OPRM1—alcohol dependence	4.82e-05	0.0296	CrCbGaD
Methylnaltrexone—Gastrointestinal disorder—Citalopram—alcohol dependence	4.77e-05	0.0147	CcSEcCtD
Methylnaltrexone—Pain—Citalopram—alcohol dependence	4.72e-05	0.0146	CcSEcCtD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—OPRM1—alcohol dependence	4.71e-05	0.00493	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—NPY—alcohol dependence	4.68e-05	0.00489	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—CHRM2—alcohol dependence	4.67e-05	0.00489	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—NPY—alcohol dependence	4.67e-05	0.00488	CbGpPWpGaD
Methylnaltrexone—Gastrointestinal pain—Citalopram—alcohol dependence	4.51e-05	0.0139	CcSEcCtD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—HTR1B—alcohol dependence	4.51e-05	0.00471	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—OPRD1—alcohol dependence	4.44e-05	0.00464	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CHRM2—alcohol dependence	4.4e-05	0.0046	CbGpPWpGaD
Methylnaltrexone—Oxycodone—OPRM1—alcohol dependence	4.39e-05	0.027	CrCbGaD
Methylnaltrexone—CYP2D6—endocrine gland—alcohol dependence	4.39e-05	0.0151	CbGeAlD
Methylnaltrexone—CYP2D6—Biological oxidations—ADH4—alcohol dependence	4.38e-05	0.00458	CbGpPWpGaD
Methylnaltrexone—Abdominal pain—Citalopram—alcohol dependence	4.36e-05	0.0135	CcSEcCtD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—CHRM2—alcohol dependence	4.34e-05	0.00453	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Phase 1 - Functionalization of compounds—ALDH2—alcohol dependence	4.33e-05	0.00452	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2E1—alcohol dependence	4.27e-05	0.00446	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—PDYN—alcohol dependence	4.25e-05	0.00444	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Oxidation by Cytochrome P450—CYP2E1—alcohol dependence	4.21e-05	0.0044	CbGpPWpGaD
Methylnaltrexone—CYP2D6—testis—alcohol dependence	4.19e-05	0.0144	CbGeAlD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—HTR1B—alcohol dependence	4.18e-05	0.00437	CbGpPWpGaD
Methylnaltrexone—CYP2D6—nervous system—alcohol dependence	4.11e-05	0.0141	CbGeAlD
Methylnaltrexone—OPRM1—Opioid Signalling—POMC—alcohol dependence	4.07e-05	0.00425	CbGpPWpGaD
Methylnaltrexone—Buprenorphine—OPRM1—alcohol dependence	4.05e-05	0.0249	CrCbGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—OPRM1—alcohol dependence	4.04e-05	0.00422	CbGpPWpGaD
Methylnaltrexone—Naloxone—OPRM1—alcohol dependence	4.02e-05	0.0247	CrCbGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—OPRD1—alcohol dependence	4e-05	0.00418	CbGpPWpGaD
Methylnaltrexone—Hydromorphone—OPRM1—alcohol dependence	3.99e-05	0.0246	CrCbGaD
Methylnaltrexone—CYP2D6—liver—alcohol dependence	3.96e-05	0.0136	CbGeAlD
Methylnaltrexone—CYP2D6—central nervous system—alcohol dependence	3.96e-05	0.0136	CbGeAlD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—NPY—alcohol dependence	3.95e-05	0.00413	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—DRD4—alcohol dependence	3.94e-05	0.00412	CbGpPWpGaD
Methylnaltrexone—CYP2D6—cerebellum—alcohol dependence	3.87e-05	0.0133	CbGeAlD
Methylnaltrexone—OPRK1—GPCR ligand binding—PDYN—alcohol dependence	3.83e-05	0.004	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—HTR1B—alcohol dependence	3.81e-05	0.00398	CbGpPWpGaD
Methylnaltrexone—Diarrhoea—Citalopram—alcohol dependence	3.78e-05	0.0117	CcSEcCtD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—CNR1—alcohol dependence	3.76e-05	0.00393	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—ADH7—alcohol dependence	3.72e-05	0.00389	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CHRM2—alcohol dependence	3.72e-05	0.00388	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—NPY—alcohol dependence	3.72e-05	0.00388	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—DRD2—alcohol dependence	3.67e-05	0.00384	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—AVP—alcohol dependence	3.66e-05	0.00383	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—DRD4—alcohol dependence	3.66e-05	0.00382	CbGpPWpGaD
Methylnaltrexone—Dizziness—Citalopram—alcohol dependence	3.65e-05	0.0113	CcSEcCtD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR1B—alcohol dependence	3.58e-05	0.00375	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—GGT2—alcohol dependence	3.57e-05	0.00373	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CRHR1—alcohol dependence	3.56e-05	0.00372	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—HTR1B—alcohol dependence	3.54e-05	0.0037	CbGpPWpGaD
Methylnaltrexone—Vomiting—Citalopram—alcohol dependence	3.51e-05	0.0108	CcSEcCtD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—CNR1—alcohol dependence	3.49e-05	0.00365	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Phase 1 - Functionalization of compounds—CYP2E1—alcohol dependence	3.46e-05	0.00362	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—HTR7—alcohol dependence	3.41e-05	0.00356	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—DRD2—alcohol dependence	3.41e-05	0.00356	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—OPRD1—alcohol dependence	3.38e-05	0.00353	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CHRM2—alcohol dependence	3.35e-05	0.0035	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—DRD4—alcohol dependence	3.33e-05	0.00348	CbGpPWpGaD
Methylnaltrexone—Nausea—Citalopram—alcohol dependence	3.28e-05	0.0101	CcSEcCtD
Methylnaltrexone—CYP2D6—Biological oxidations—ADH1B—alcohol dependence	3.26e-05	0.00341	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—PDYN—alcohol dependence	3.24e-05	0.00338	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—CNR1—alcohol dependence	3.18e-05	0.00332	CbGpPWpGaD
Methylnaltrexone—CYP2D6—brain—alcohol dependence	3.14e-05	0.0108	CbGeAlD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—NPY—alcohol dependence	3.14e-05	0.00328	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—DRD4—alcohol dependence	3.13e-05	0.00327	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—DRD2—alcohol dependence	3.1e-05	0.00324	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—AVP—alcohol dependence	3.1e-05	0.00324	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—DRD4—alcohol dependence	3.09e-05	0.00323	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—OPRM1—alcohol dependence	3.07e-05	0.00321	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR1B—alcohol dependence	3.03e-05	0.00317	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CRHR1—alcohol dependence	3.01e-05	0.00315	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CNR1—alcohol dependence	2.99e-05	0.00313	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—CNR1—alcohol dependence	2.95e-05	0.00308	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—DRD2—alcohol dependence	2.92e-05	0.00305	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR7—alcohol dependence	2.92e-05	0.00305	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—DRD2—alcohol dependence	2.88e-05	0.00301	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—HTR7—alcohol dependence	2.88e-05	0.00301	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—alcohol dependence	2.85e-05	0.00298	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—OPRK1—alcohol dependence	2.84e-05	0.00297	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CHRM2—alcohol dependence	2.83e-05	0.00296	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—NPY—alcohol dependence	2.83e-05	0.00296	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—HTR1B—alcohol dependence	2.73e-05	0.00285	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CRH—alcohol dependence	2.73e-05	0.00285	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—MAOB—alcohol dependence	2.7e-05	0.00283	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—alcohol dependence	2.65e-05	0.00277	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—OPRK1—alcohol dependence	2.58e-05	0.0027	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CNR1—alcohol dependence	2.53e-05	0.00264	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR7—alcohol dependence	2.47e-05	0.00258	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—alcohol dependence	2.47e-05	0.00258	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—AVP—alcohol dependence	2.46e-05	0.00257	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—POMC—alcohol dependence	2.43e-05	0.00254	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—NPY—alcohol dependence	2.39e-05	0.0025	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—HTR2A—alcohol dependence	2.39e-05	0.00249	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—DRD4—alcohol dependence	2.39e-05	0.00249	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—HTR1B—alcohol dependence	2.31e-05	0.00241	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CRH—alcohol dependence	2.31e-05	0.00241	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—ALDH2—alcohol dependence	2.3e-05	0.0024	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—alcohol dependence	2.29e-05	0.00239	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CNR1—alcohol dependence	2.28e-05	0.00238	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—OPRD1—alcohol dependence	2.26e-05	0.00236	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—HTR7—alcohol dependence	2.22e-05	0.00232	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—DRD2—alcohol dependence	2.22e-05	0.00232	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PDYN—alcohol dependence	2.17e-05	0.00226	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—AVP—alcohol dependence	2.08e-05	0.00217	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—POMC—alcohol dependence	2.06e-05	0.00215	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—POMC—alcohol dependence	2.05e-05	0.00215	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—OPRD1—alcohol dependence	2.05e-05	0.00214	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR2A—alcohol dependence	2.04e-05	0.00214	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—HTR2A—alcohol dependence	2.02e-05	0.00211	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—DRD4—alcohol dependence	2.02e-05	0.00211	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CRHR1—alcohol dependence	2.01e-05	0.0021	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PDYN—alcohol dependence	1.97e-05	0.00205	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CNR1—alcohol dependence	1.93e-05	0.00201	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—OPRD1—alcohol dependence	1.91e-05	0.00199	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CHRM2—alcohol dependence	1.89e-05	0.00198	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—DRD2—alcohol dependence	1.88e-05	0.00196	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—HTR7—alcohol dependence	1.88e-05	0.00196	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—AVP—alcohol dependence	1.87e-05	0.00196	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Phase 1 - Functionalization of compounds—POMC—alcohol dependence	1.85e-05	0.00194	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—CYP2E1—alcohol dependence	1.84e-05	0.00192	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PDYN—alcohol dependence	1.83e-05	0.00191	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CRHR1—alcohol dependence	1.83e-05	0.00191	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metapathway biotransformation—CYP2E1—alcohol dependence	1.81e-05	0.0019	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—OPRM1—alcohol dependence	1.74e-05	0.00182	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—POMC—alcohol dependence	1.74e-05	0.00181	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—OPRD1—alcohol dependence	1.73e-05	0.00181	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—alcohol dependence	1.73e-05	0.00181	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CHRM2—alcohol dependence	1.72e-05	0.0018	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CRHR1—alcohol dependence	1.7e-05	0.00178	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—GGT1—alcohol dependence	1.69e-05	0.00176	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PDYN—alcohol dependence	1.66e-05	0.00174	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—POMC—alcohol dependence	1.63e-05	0.00171	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CHRM2—alcohol dependence	1.6e-05	0.00167	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—NPY—alcohol dependence	1.6e-05	0.00167	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—AVP—alcohol dependence	1.58e-05	0.00165	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—OPRM1—alcohol dependence	1.58e-05	0.00165	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—HTR2A—alcohol dependence	1.56e-05	0.00163	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CRHR1—alcohol dependence	1.54e-05	0.00161	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CRH—alcohol dependence	1.54e-05	0.00161	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—HTR1B—alcohol dependence	1.54e-05	0.00161	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—OPRK1—alcohol dependence	1.52e-05	0.00159	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—MAOA—alcohol dependence	1.51e-05	0.00158	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CHRM2—alcohol dependence	1.45e-05	0.00152	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—NPY—alcohol dependence	1.45e-05	0.00152	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CRH—alcohol dependence	1.4e-05	0.00146	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—HTR1B—alcohol dependence	1.4e-05	0.00146	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—POMC—alcohol dependence	1.38e-05	0.00144	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—NPY—alcohol dependence	1.35e-05	0.00141	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—DRD4—alcohol dependence	1.35e-05	0.00141	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—HTR2A—alcohol dependence	1.32e-05	0.00138	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—HTR1B—alcohol dependence	1.3e-05	0.00136	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CRH—alcohol dependence	1.3e-05	0.00136	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CNR1—alcohol dependence	1.29e-05	0.00135	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—DRD2—alcohol dependence	1.26e-05	0.00131	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—HTR7—alcohol dependence	1.26e-05	0.00131	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—POMC—alcohol dependence	1.24e-05	0.0013	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—NPY—alcohol dependence	1.23e-05	0.00128	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—DRD4—alcohol dependence	1.22e-05	0.00128	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—OPRD1—alcohol dependence	1.21e-05	0.00127	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—HTR1B—alcohol dependence	1.18e-05	0.00124	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CRH—alcohol dependence	1.18e-05	0.00124	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CNR1—alcohol dependence	1.17e-05	0.00122	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PDYN—alcohol dependence	1.16e-05	0.00121	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—HTR7—alcohol dependence	1.14e-05	0.00119	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—DRD2—alcohol dependence	1.14e-05	0.00119	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—DRD4—alcohol dependence	1.14e-05	0.00119	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CNR1—alcohol dependence	1.09e-05	0.00114	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CRHR1—alcohol dependence	1.08e-05	0.00113	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—WASF2—alcohol dependence	1.08e-05	0.00113	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ADH6—alcohol dependence	1.06e-05	0.00111	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—DRD2—alcohol dependence	1.06e-05	0.00111	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—HTR7—alcohol dependence	1.06e-05	0.00111	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—AVP—alcohol dependence	1.06e-05	0.00111	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—POMC—alcohol dependence	1.05e-05	0.0011	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—WASF1—alcohol dependence	1.04e-05	0.00108	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—DRD4—alcohol dependence	1.03e-05	0.00108	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—OPRD1—alcohol dependence	1.02e-05	0.00107	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CHRM2—alcohol dependence	1.02e-05	0.00106	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CNR1—alcohol dependence	9.88e-06	0.00103	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—POMC—alcohol dependence	9.85e-06	0.00103	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PDYN—alcohol dependence	9.82e-06	0.00103	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—DRD2—alcohol dependence	9.64e-06	0.00101	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—HTR7—alcohol dependence	9.64e-06	0.00101	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—AVP—alcohol dependence	9.6e-06	0.001	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—OPRM1—alcohol dependence	9.32e-06	0.000974	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—WASF2—alcohol dependence	9.13e-06	0.000954	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CRHR1—alcohol dependence	9.13e-06	0.000954	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AVP—alcohol dependence	8.94e-06	0.000934	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ADH1A—alcohol dependence	8.81e-06	0.00092	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—HTR2A—alcohol dependence	8.8e-06	0.00092	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—WASF1—alcohol dependence	8.75e-06	0.000914	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CHRM2—alcohol dependence	8.58e-06	0.000897	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NPY—alcohol dependence	8.58e-06	0.000896	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CRH—alcohol dependence	8.28e-06	0.000865	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HTR1B—alcohol dependence	8.28e-06	0.000865	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AVP—alcohol dependence	8.11e-06	0.000848	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—HTR2A—alcohol dependence	7.99e-06	0.000835	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ADH4—alcohol dependence	7.49e-06	0.000782	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—HTR2A—alcohol dependence	7.44e-06	0.000777	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NPY—alcohol dependence	7.25e-06	0.000758	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—DRD4—alcohol dependence	7.23e-06	0.000756	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—POMC—alcohol dependence	7.03e-06	0.000734	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CRH—alcohol dependence	6.99e-06	0.000731	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HTR1B—alcohol dependence	6.99e-06	0.000731	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CNR1—alcohol dependence	6.91e-06	0.000722	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—HTR2A—alcohol dependence	6.75e-06	0.000706	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—DRD2—alcohol dependence	6.74e-06	0.000704	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HTR7—alcohol dependence	6.74e-06	0.000704	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—POMC—alcohol dependence	6.38e-06	0.000667	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ADH7—alcohol dependence	6.37e-06	0.000665	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—DRD4—alcohol dependence	6.11e-06	0.000639	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GGT2—alcohol dependence	6.1e-06	0.000638	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—POMC—alcohol dependence	5.94e-06	0.000621	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CNR1—alcohol dependence	5.84e-06	0.00061	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—DRD2—alcohol dependence	5.7e-06	0.000595	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HTR7—alcohol dependence	5.7e-06	0.000595	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AVP—alcohol dependence	5.67e-06	0.000593	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ADH1B—alcohol dependence	5.58e-06	0.000583	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—POMC—alcohol dependence	5.39e-06	0.000564	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AVP—alcohol dependence	4.79e-06	0.000501	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HTR2A—alcohol dependence	4.72e-06	0.000493	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—MAOB—alcohol dependence	4.63e-06	0.000483	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HTR2A—alcohol dependence	3.99e-06	0.000417	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ALDH2—alcohol dependence	3.93e-06	0.000411	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—POMC—alcohol dependence	3.77e-06	0.000394	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GOT2—alcohol dependence	3.34e-06	0.00035	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—POMC—alcohol dependence	3.19e-06	0.000333	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP2E1—alcohol dependence	3.14e-06	0.000329	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GGT1—alcohol dependence	2.89e-06	0.000302	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GOT1—alcohol dependence	2.89e-06	0.000302	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—MAOA—alcohol dependence	2.59e-06	0.00027	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EP300—alcohol dependence	2.5e-06	0.000261	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EP300—alcohol dependence	2.11e-06	0.000221	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—POMC—alcohol dependence	1.68e-06	0.000176	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—EP300—alcohol dependence	1.12e-06	0.000117	CbGpPWpGaD
